Cargando…

TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies

Immune evasion through up-regulating checkpoint inhibitory receptors on T cells plays an essential role in tumor initiation and progression. Therefore, immunotherapy, including immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1) and chimeric antigen receptor T cell (CAR-T) t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Shenhe, Zhang, Ye, Zhou, Fengping, Chen, Xiaochang, Sheng, Jianpeng, Zhang, Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9807865/ https://www.ncbi.nlm.nih.gov/pubmed/36605439 http://dx.doi.org/10.3389/fonc.2022.1091782

Ejemplares similares

Role of CD155/TIGIT in Digestive Cancers: Promising Cancer Target for Immunotherapy
por: Wang, Daijun, et al.
Publicado: (2022)

TIGIT as a Promising Therapeutic Target in Autoimmune Diseases
por: Yue, Chenran, et al.
Publicado: (2022)

TIGIT in cancer immunotherapy
por: Chauvin, Joe-Marc, et al.
Publicado: (2020)

A new approach to overcoming resistance to immunotherapy: nanotechnology
por: Shao, Jiangbo, et al.
Publicado: (2023)

CAR-T cell therapy for hematological malignancies: History, status and promise
por: Wang, Chao, et al.
Publicado: (2023)

Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
por: Rotte, Anand, et al.
Publicado: (2021)

Autophagy, autophagy-associated adaptive immune responses and its role in hematologic malignancies
por: You, Liangshun, et al.
Publicado: (2016)

Update in TIGIT Immune-Checkpoint Role in Cancer
por: Annese, Tiziana, et al.
Publicado: (2022)

Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Targeting Lysosomes in Cancer as Promising Strategy to Overcome Chemoresistance—A Mini Review
por: Geisslinger, Franz, et al.
Publicado: (2020)

Bispecific T cell engagers targeting CD20/CD3 in B-cell lymphoma: latest updates from 2023 EHA annual meeting
por: Jin, Shenhe, et al.
Publicado: (2023)

Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways
por: Mountzios, Giannis, et al.
Publicado: (2022)

Ferroptosis in hematological malignant tumors
por: Liu, Yong, et al.
Publicado: (2023)

From CAR-T Cells to CAR-NK Cells: A Developing Immunotherapy Method for Hematological Malignancies
por: Lu, Hui, et al.
Publicado: (2021)

Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance
por: Konings, Katrien, et al.
Publicado: (2020)

The promise of targeting heme and mitochondrial respiration in normalizing tumor microenvironment and potentiating immunotherapy
por: Akter, Zakia, et al.
Publicado: (2023)

4-1BB: A promising target for cancer immunotherapy
por: Kim, Alyssa Min Jung, et al.
Publicado: (2022)

B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?
por: Zhang, Wei, et al.
Publicado: (2021)

Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes
por: Meng, Fanqiao, et al.
Publicado: (2020)

Myeloid-Derived Suppressor Cells as Therapeutic Target in Hematological Malignancies
por: De Veirman, Kim, et al.
Publicado: (2014)

Structural Variants as a Basis for Targeted Therapies in Hematological Malignancies
por: Schütte, Judith, et al.
Publicado: (2019)

Cancer-associated fibroblasts in hematologic malignancies: elucidating roles and spotlighting therapeutic targets
por: Ding, Ziyang, et al.
Publicado: (2023)

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
por: Cai, Letong, et al.
Publicado: (2023)

Neoantigens in Hematological Malignancies—Ultimate Targets for Immunotherapy?
por: Roerden, Malte, et al.
Publicado: (2019)

Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
por: Zhang, Jin, et al.
Publicado: (2018)

PD-1 and TIGIT Are Highly Co-Expressed on CD8(+) T Cells in AML Patient Bone Marrow
por: Xu, Ling, et al.
Publicado: (2021)

Editorial: Strategies to overcome tumor evasion and resistance to immunotherapies by targeting immune suppressor cells
por: Saida, Yu, et al.
Publicado: (2023)

Semaphorins and Their Receptors in Hematological Malignancies
por: Wei, Li, et al.
Publicado: (2019)

WNT Signaling in Hematological Malignancies
por: Frenquelli, Michela, et al.
Publicado: (2020)

Editorial: Reviews in hematologic malignancies
por: Saraceni, Francesco, et al.
Publicado: (2022)

Checkpoint inhibition in hematologic malignancies
por: Tsumura, Aaron, et al.
Publicado: (2023)

The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?
por: Ganjalikhani Hakemi, Mazdak, et al.
Publicado: (2020)

Genetically Engineered T-Cells for Malignant Glioma: Overcoming the Barriers to Effective Immunotherapy
por: Chuntova, Pavlina, et al.
Publicado: (2019)

Can Natural Products be Used to Overcome the Limitations of Colorectal Cancer Immunotherapy?
por: Dong, Jiahuan, et al.
Publicado: (2022)

The immunotherapy advancement targeting malignant blastomas in early childhood
por: Zang, Bolun, et al.
Publicado: (2023)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
por: Tasian, Sarah K., et al.
Publicado: (2014)

Cap-Independent Translation in Hematological Malignancies
por: Horvilleur, Emilie, et al.
Publicado: (2015)

Multiple Roles of Glycans in Hematological Malignancies
por: Pang, Xingchen, et al.
Publicado: (2018)

PHF6 Mutations in Hematologic Malignancies
por: Kurzer, Jason H., et al.
Publicado: (2021)

The hedgehog pathway in hematopoiesis and hematological malignancy
por: Lemos, Tucker, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4vrv6sfdmbcku58homr46g2sqt